AstraZeneca drops 7% on Bristol Myers merger report
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- AstraZeneca shares dropped as much as 7% on Monday after a report that the company held preliminary merger talks with Bristol Myers Squibb in a potential deal worth roughly $400 billion, which would rank among the largest pharma tie-ups ever.
- Neither company confirmed the report; AstraZeneca declined to comment while Bristol Myers Squibb did not immediately respond to CNBC's request outside normal U.S. business hours.
- Jefferies analysts said they were "perplexed" given AstraZeneca's strong growth and innovation profile, adding that "if there is one company that doesn't need financial engineering, it's AZ."
- Bristol Myers Squibb shares rose 6% in U.S. premarket trading; the company faces patent expirations on top-selling drugs Eliquis and cancer medicine Opdivo, with declining growth expected from next year.
- Under CEO Pascal Soriot, AstraZeneca has grown to a market cap of $264 billion since 2012, with the company targeting $80 billion in 2030 sales — up from $58.7 billion last year.
- RBC Capital Markets noted that upcoming trial readouts for Bristol Myers' milvexian and label expansion for Cobenfy make pipeline synergies between the two companies uncertain.
- Jefferies flagged that the combined oncology portfolio would be the broadest in the industry, potentially attracting antitrust scrutiny, though the two companies' pipelines are largely complementary.
Why it matters: A merger would rank among the largest pharma deals ever, but the timing puzzles analysts: AstraZeneca is one of the industry's strongest growth stories ($264B market cap, $80B sales target by 2030), while Bristol Myers faces patent cliffs on Eliquis and Opdivo. Jefferies and RBC flagged antitrust risk and uncertain pipeline synergies, making this a high-stakes combination that could face both regulatory and strategic headwinds.
